What are the potential side effects and risks of omega‑3 (EPA/DHA) supplementation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Omega-3 Side Effects

Omega-3 fatty acid supplementation (EPA/DHA) carries a small but clinically significant increased risk of atrial fibrillation and major bleeding, with EPA monotherapy showing higher bleeding risk than EPA+DHA combinations. 1

Primary Safety Concerns

Cardiovascular Risks

Atrial Fibrillation (AF)

  • Omega-3 supplementation increases AF risk by approximately 25% (RR 1.25-1.35) 1
  • This risk is consistent across all recent trials (REDUCE-IT, STRENGTH, OMEMI) 2
  • EPA monotherapy shows higher AF risk (RR 1.35) compared to EPA+DHA combinations 3
  • Most pronounced in patients with pre-existing history of atrial fibrillation 1

Bleeding Events

  • Small increased risk of major bleeding with both EPA alone and EPA+DHA 1
  • EPA monotherapy (prescription formulations) carries higher bleeding risk (RR 1.49) than EPA+DHA 3
  • Particularly concerning in patients taking anticoagulants or antiplatelet medications 1
  • Requires increased monitoring when combined with blood thinners 1

Gastrointestinal Effects

The most common side effects are gastrointestinal:

  • Eructation (belching/fishy taste): More common with EPA+DHA combinations 4
  • Diarrhea: Most frequent GI complaint (24.7% vs 14.7% placebo in STRENGTH trial) 2
  • Nausea: More common with EPA+DHA products 4
  • General GI disturbances: Lead to moderate increase in treatment discontinuation (27 more per 1000 patients) 1

Metabolic and Laboratory Changes

Lipid Effects

  • EPA+DHA combinations may increase LDL-C levels, requiring periodic monitoring 1
  • LDL-C elevation more pronounced with EPA+DHA products (mean difference 4.1 mg/dL) 4

Other Laboratory Abnormalities 4

  • Elevated fasting blood sugar
  • Elevated alanine transaminase (liver enzyme)
  • Elevated blood urea nitrogen
  • Decreased hemoglobin and hematocrit (mild)

Dermatologic Effects

  • Skin eruptions, itching, exanthema, or eczema more common than placebo 4

Dose-Dependent Considerations

At doses ≥3 grams/day (particularly the 4g doses used in clinical trials):

  • Higher risk of excessive bleeding 5
  • Should only be used under physician supervision 5
  • Most safety data comes from trials using 1.8-4g/day doses 1

Very high "Eskimo" intakes could cause excessive bleeding in some individuals 5

Important Clinical Caveats

Monitoring Requirements

When prescribing omega-3 fatty acids, monitor for:

  • Signs of atrial fibrillation (palpitations, irregular pulse)
  • Bleeding events, especially in patients on anticoagulation
  • LDL-C levels periodically (particularly with EPA+DHA) 1
  • Liver function tests in patients with hepatic impairment taking EPA+DHA 1

Contraindications and Cautions

  • Fish/seafood allergy: Use with extreme caution
  • Anticoagulant therapy: Increased bleeding risk requires careful risk-benefit assessment 1
  • History of atrial fibrillation: Higher risk of AF recurrence 1
  • Severe hypertriglyceridemia (≥500 mg/dL): Insufficient safety data 1

Environmental Contaminants (Dietary Fish Sources)

While prescription omega-3 supplements are methylmercury-free 5, dietary fish may contain:

  • Methylmercury
  • Polychlorinated biphenyls (PCBs)
  • Dioxins
  • Other environmental contaminants

Risk varies by life stage 5:

  • Children, pregnant/nursing women: Avoiding contaminated fish is higher priority due to mercury exposure risk
  • Middle-aged/older adults: Benefits of fish consumption outweigh risks when following FDA/EPA guidelines
  • Strategy: Eat variety of fish to minimize pollutant exposure

Formulation Differences

EPA monotherapy (icosapent ethyl) shows:

  • Higher bleeding risk than EPA+DHA 3
  • Higher AF risk (RR 1.35) 3
  • More dysgeusia (fishy taste) 4

EPA+DHA combinations show:

  • More GI side effects (belching, nausea) 4
  • Greater LDL-C elevation 4
  • Lower bleeding risk than EPA alone 3

Over-the-Counter Products

Non-prescription fish oil products 1:

  • Highly variable EPA/DHA content
  • Not FDA-regulated
  • Quality and purity uncertain
  • May not have same safety profile as prescription formulations

Serious Adverse Events

No definite evidence of serious adverse events emerged from meta-analysis of 21 RCTs with 24,460 participants 4, but the AF and bleeding risks, while relatively small in absolute terms, represent clinically meaningful safety concerns requiring shared decision-making with patients 1.

References

1
Guideline

american association of clinical endocrinology clinical practice guideline on pharmacologic management of adults with dyslipidemia.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2025

Related Questions

What is the recommended daily dose of combined EPA and DHA omega‑3 fatty acids from fish oil for a healthy adult?
What is the recommended high‑dose omega‑3 (EPA and DHA) supplementation regimen, including dosing, monitoring, and safety precautions?
What is the recommended dose of omega‑3 (EPA/DHA) for adults and what safety precautions should be considered?
Are omega‑3 fatty acid supplements (eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) derived from cod, cod liver, or fish oil safe for a typical healthy adult?
Is it safe to prescribe omega-3 fatty acids (EPA and DHA) to a 15-year-old patient?
What is the most reliable bedside test to diagnose an Achilles tendon rupture?
What is the appropriate evaluation and management for a patient with a prolonged prothrombin time and elevated alkaline phosphatase?
In a comatose patient, what do decorticate, decerebrate, and flaccid posturing indicate and how should they be managed?
How should pimecrolimus 1% cream be applied for perioral dermatitis, and what are the contraindications?
How should Oplzelura (ruxolitinib) cream be applied, what are its contraindications, and what alternative treatments are recommended?
What are the differential diagnoses for calf pain?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.